for advanced HNSCC are suboptimal with few targeted therapies available.1
6%-16%3,4
~2 MONTHS3,4
5-8 MONTHS3,4
*Based on patients with R/M HNSCC who progressed on prior therapies in 2 studies. Outcomes may differ with other treatment regimens such as combination, single-agent, or targeted therapies.
Patient enrollment is open for the following clinical trials: